TriangleFOR PATIENTS · SOURCE READING
Targeted therapy
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Mantle-cell-specific source passages within broader non-Hodgkin lymphoma sections Only selected blocks explicitly name mantle cell lymphoma. Full owning sections include other lymphomas and must not be relabeled mantle-cell-only.
Context from the original source
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Monoclonal antibody therapy, proteasome inhibitor therapy, and kinase inhibitor therapy are types of targeted therapy used to treat non-Hodgkin lymphoma.
Source links and citations
This intact source passage also discusses another lymphoma. Retained to preserve distinctions such as established use versus investigation; it is not a mantle-cell-only statement.
Proteasome inhibitor therapy: This treatment blocks the action of proteasomes in cancer cells. Proteasomes remove proteins no longer needed by the cell. When the proteasomes are blocked, the proteins build up in the cell and may cause the cancer cell to die. Bortezomib or ixazomib is used to decrease how much immunoglobulin M is in the blood after cancer treatment for lymphoplasmacytic lymphoma (Waldenström macroglobulinemia). It is also being studied to treat relapsed mantle cell lymphoma.
Source links and citations
This intact source passage also discusses another lymphoma. Retained to preserve distinctions such as established use versus investigation; it is not a mantle-cell-only statement.
Kinase inhibitor therapy: This treatment blocks certain proteins, which may help keep lymphoma cells from growing and may kill them. Kinase inhibitor therapies include:
Ibrutinib, acalabrutinib, and zanubrutinib, which are types of Bruton tyrosine kinase inhibitor therapy. They are used to treat mantle cell lymphoma. Ibrutinib and acalabrutinib are also used to treat lymphoplasmacytic lymphoma, and zanubrutinib is being studied to treat it.
Source links and citations
B-cell lymphoma-2 (BCL-2) inhibitor therapy: Venetoclax may be used to treat mantle cell lymphoma. It blocks the action of a protein called BCL-2 and may help kill cancer cells.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice